Current Vascular Pharmacology

Author(s): Panagiotis Anagnostis*, Dimitri P. Mikhailidis, Ales Blinc, Mojca Jensterle, Mateja K. Ježovnik, Gerit-Holger Schernthaner, Pier Luigi Antignani, Katica Bajuk Studen, Miso Šabović and Pavel Poredos

DOI: 10.2174/0115701611263345230919122907

DownloadDownload PDF Flyer Cite As
The Effect of Menopause and Menopausal Hormone Therapy on the Risk of Peripheral Artery Disease

Page: [293 - 296] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Peripheral artery disease (PAD), defined as lower extremity arterial disease, constitutes an underestimated aspect of the menopause-associated risk of atherosclerotic cardiovascular disease (ASCVD). Accumulation of ASCVD risk factors, such as atherogenic dyslipidaemia, diabetes, and arterial hypertension, after the transition to menopause may contribute to atherosclerotic plaque formation in peripheral arteries. However, inconsistency exists among studies as to whether transition to menopause increases the risk of PAD, although early menopause (<45 years) or premature ovarian insufficiency may accelerate peripheral atherosclerotic plaque formation. Menopausal hormone therapy may decrease the risk of PAD if administered early (i.e., within the first 5-6 years after last menstruation), whereas it has no effect in women with established ASCVD.

Keywords: Menopause, premature ovarian insufficiency, menopausal hormone therapy, peripheral artery disease.